careers & recruitment

People Recent moves of note in and around the biotech and pharma industries.

Janssen R&D has announced the Silverback Therapeutics has announced the appointment appointment of Najat Khan as chief data of Laura Shawver (photo) as president, CEO and member science officer. She was most recently the of the board of directors. She brings more than 25 years as company’s global head of strategy and a scientist, biotech leader and patient advocate to the role. operations in R&D, but will now also now Shawver was most recently CEO and director of Synthorx run the data science side, which aims to from 2017 until its acquisition by Sanofi in January for make R&D more efficient by mining data $2.5 billion. Previously, she was CEO and director of Cleave careers & recruitment in hopes of finding more pipeline winners Biosciences, entrepreneur-in-residence for 5AM Ventures, more readily. CEO and director of Phenomix, and president of Sugen. She is a director of Relay Therapeutics, as well as board chair of Cleave Therapeutics. Sangamo Therapeutics has named “With her range of strategic expertise, demonstrated success raising capital, scientific D. Mark McClung as executive vice acumen, and broad drug development experience, Laura is the perfect fit for Silverback,” president and chief business officer. said Peter Thompson, OrbiMed partner, cofounder and chairman of Silverback McClung was previously vice president Therapeutics. “I, along with Silverback’s entire board, look forward to working with and general manager of global oncology Laura and our exceptional leadership team to advance Silverback’s pipeline and deliver commercial at and, before on the promise to dramatically improve the lives of patients.” that, chief commercial officer at Onyx Pharmaceuticals. Sangamo also announced the departure of executive vice president of Patrick Bergstedt has joined served as chancellor of the University of corporate strategy Stephane Boissel at the Therapeutics as senior vice president, California, San Francisco until becoming end of July. Boissel joined the company in commercial vaccines. He has held various CEO of the Bill & Melinda Gates Foundation 2018 after serving as CEO of TxCell. leadership positions with the infectious from 2014 until 2020. Most recently, diseases and global human health groups Desmond-Hellman joined the board of Roche has appointed at Merck & Co. since 2001, most recently directors of in April. Aviv Regev (photo) serving as head of global marketing & head of commercial operations: vaccines. Moderna Cellia Habita has joined Immodulon Research and Early also announced the appointments of Therapeutics as chief medical officer. Development (gRED) as Jacqueline Miller as senior vice president, She was most recently president and CEO of 1 August, succeeding infectious disease development and of Arianne Clinical Research. Previous roles Michael Varney, who Charbel Haber as senior vice president, include director of product development at is retiring from the regulatory affairs. Miller joins the company Immusol and senior vice president of clinical company at the end of from GlaxoSmithKline, where she was most and medical affairs at Adventrx. July. Regev, currently chair of the faculty, recently vice president and head, clinical core institute member and member of the R&D and epidemiology, and Haber was Helen Horton has been appointed executive leadership team of the Broad previously head, global regulatory affairs– chief research officer of Hampton, Institute of MIT and Harvard, as well as immunology and neurology at EMD Serono. UK–based Touchlight. She has over 20 years professor of biology at MIT and investigator of experience in immunogenetics, immune of the Howard Hughes Medical Institute, Cellectis has appointed Carrie Brownstein modulation and infectious diseases. will become a member of Roche’s enlarged as chief medical officer. Brownstein most She joins Touchlight from Johnson & corporate executive committee. recently served as vice president, global Johnson, where she served as a senior clinical R&D, therapeutic area head for scientific director. Caribou Biosciences has appointed myeloid diseases at Celgene. Cherry Thomas senior vice president Xilio Therapeutics has named Martin H. of clinical development, a newly created Ohana Biosciences has appointed Ramiro Huber as chief medical officer. He most position. Thomas joins Caribou from Array Castro-Santamaria as chief medical officer. recently served as senior vice president and Biopharma, where she most recently served Castro-Santamaria most recently served as chief medical officer at Tesaro before its as vice president of clinical development of vice president of clinical sciences and head acquisition by GlaxoSmithKline. the company’s oncology division. of rheumatology at GlaxoSmithKline. Before that he was at Boehringer Ingelheim and Former founding CSO of Nimbus Elicio Therapeutics has named Pharmacia (later Pfizer). Therapeutics Rosana Kapeller has Esther Welkowsky vice president, joined new startup Rome Therapeutics clinical operations. Previously, Welkowsky Sue Desmond-Hellmann has joined GV, the as CEO. Kapeller was most recently served as executive director of clinical venture group formerly known as Google entrepreneur-in-residence at venture capital operations at Allogene. Ventures, as a senior adviser. She spent firm GV, which, along with Arch Ventures 14 years at Genentech, leaving as president and Partners Innovation Fund, are behind Published online: 9 June 2020 of product development in 2009. She then Rome’s $50 million in series A funding. https://doi.org/10.1038/s41587-020-0557-5

764 Nature Biotechnology | VOL 38 | June 2020 | 758–764 | www.nature.com/naturebiotechnology